Comparative survival analysis of patients with HER2-low and HER2-positive metastatic breast cancer with or without brain metastases treated with trastuzumab deruxtecan

被引:0
|
作者
Podder, Vivek
Ranjan, Tulika
Bardhan, Mainak
McCracken, Andrea
Hurmiz, Charlie
Ganiyani, Mohammad Arfat
Ahmad, Shahzaib
Mahtani, Reshma L.
Ahluwalia, Manmeet Singh
机构
[1] Baptist Hlth South Florida, Miami Canc Inst, Miami, FL USA
[2] Guardian Res Network, Spartanburg, SC USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
1036
引用
收藏
页数:1
相关论文
共 50 条
  • [31] Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
    Shitara, Kohei
    Bang, Yung-Jue
    Iwasa, Satoru
    Sugimoto, Naotoshi
    Ryu, Min-Hee
    Sakai, Daisuke
    Chung, Hyun-Cheol
    Kawakami, Hisato
    Yabusaki, Hiroshi
    Lee, Jeeyun
    Saito, Kaku
    Kawaguchi, Yoshinori
    Kamio, Takahiro
    Kojima, Akihito
    Sugihara, Masahiro
    Yamaguchi, Kensei
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (25) : 2419 - 2430
  • [32] Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab
    P. S. Blanchette
    D. N. Desautels
    G. R. Pond
    J. M. S. Bartlett
    S. Nofech-Mozes
    M. J. Yaffe
    K. I. Pritchard
    Breast Cancer Research and Treatment, 2018, 170 : 169 - 177
  • [33] Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with Trastuzumab
    Blanchette, P. S.
    Desautels, D. N.
    Pond, G.
    Bartlett, J. M. S.
    Nofech-Mozes, S.
    Yaffe, M.
    Pritchard, K. I.
    CANCER RESEARCH, 2017, 77
  • [34] Safety of trastuzumab deruxtecan and radiation therapy combination in HER2-positive metastatic breast cancer patients
    Visani, L.
    Ratosa, I.
    Ribnikar, D.
    Becherini, C.
    Bertini, N.
    Bonaparte, I.
    Stefanovski, D.
    Dobnikar, N.
    Desideri, I.
    Mattioli, C.
    Valzano, M.
    Banini, M.
    Salvestrini, V.
    Bernini, M.
    Tommasi, C.
    Nori, J.
    Orzalesi, L.
    Bianchi, S.
    Livi, L.
    Meattini, I.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 60 - 61
  • [35] Trastuzumab deruxtecan, its efficacy in patients with metastatic HER2-positive breast cancer: a systematic review
    Fernhandho, V.
    Jhoputri, C. Fricilia
    Julian, L.
    Kurniawan, A.
    Huang, I.
    ANNALS OF ONCOLOGY, 2024, 35 : S1337 - S1337
  • [36] Response to trastuzumab deruxtecan in a patient with HER2-low metastatic breast cancer previously treated with sacituzumab govitecan
    Testa, Stefano
    Dickerson, James C.
    Telli, Melinda
    CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2023, 11
  • [37] Treatment of HER2-Positive Breast Cancer with Brain Metastases Using Anlotinib and Trastuzumab Deruxtecan: A Case Report
    Chen, Yuanping
    Liu, Chao
    Wen, Xinglin
    Wang, Chen
    He, Jing
    INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2024, 16 : 1277 - 1283
  • [38] Trastuzumab-Deruxtecan in the Therapy of HER2-positive Breast Cancer
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (06) : 365 - 365
  • [39] Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer
    Nakajima, Hiromichi
    Harano, Kenichi
    Nakai, Tokiko
    Kusuhara, Shota
    Nakao, Takehiro
    Funasaka, Chikako
    Kondoh, Chihiro
    Matsubara, Nobuaki
    Naito, Yoichi
    Hosono, Ako
    Mitsunaga, Shuichi
    Ishii, Genichiro
    Mukohara, Toru
    BREAST, 2022, 61 : 136 - 144
  • [40] Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
    Bartsch, Rupert
    Berghoff, Anna Sophie
    Furtner, Julia
    Marhold, Maximilian
    Bergen, Elisabeth Sophie
    Roider-Schur, Sophie
    Starzer, Angelika Martina
    Forstner, Heidrun
    Rottenmanner, Beate
    Dieckmann, Karin
    Bago-Horvath, Zsuzsanna
    Haslacher, Helmuth
    Widhalm, Georg
    Ilhan-Mutlu, Aysegul
    Minichsdorfer, Christoph
    Fuereder, Thorsten
    Szekeres, Thomas
    Oehler, Leopold
    Gruenberger, Birgit
    Singer, Christian F.
    Weltermann, Ansgar
    Puhr, Rainer
    Preusser, Matthias
    NATURE MEDICINE, 2022, 28 (09) : 1840 - +